Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Loss

v3.20.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 13,489 $ 9,135
General and administrative expenses 8,718 3,360
Operating loss 22,207 12,495
Finance expenses (income), net (1,644) 225
Loss before income tax 20,563 12,720
Income tax
Net Loss $ 20,563 $ 12,720
Basic and diluted loss per Ordinary Shares $ 3.66 $ 7.62
Weighted average number of Ordinary Shares outstanding, basic and diluted 5,615,856 2,002,464